The global cart cell therapy market size was valued at USD 355.1 million in 2018 and is anticipated to grow at a CAGR of 29.4% during the forecast period. CAR-T cell therapy is the healing significant treatment for cancer patients. Cart cell therapy is an emerging treatment since the introduction of chemotherapy and is one of the biggest revolutions for the patients. Foremost, CAR-T is a type of immunotherapy where doctors collect immune cells from a patient's body and then modify them in a laboratory thereafter then the doctor provides them the supremacy to easily diagnose and kill cancer cells from the patient body.

Key Developments in Cart Cell Therapy Market:
• In April 2019, Autolus Therapeutics PLC was assigned an orphan drug designation by the US FDA for the treatment of acute lymphoblastic leukemia (ALL) to autolus enriched T-cells, genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22.
• In April 2019, Cellectis received approval from the US FDA to initiate a Phase 1 clinical trial for UCARTCS1, in patients with multiple myeloma (MM).
• In May 2018, Kite Pharma leased a new cell therapy engineering facility in the Netherlands. With this, the company is aiming to strengthen its position in the global market for CAR T-cell therapy.

The key leading players in the market include Novartis AG, Kite Pharma, Mustang Bio, Sorrento Therapeutics, CARsgen Therapeutics, Autolus Therapeutics, Pfizer Inc., Cellectis, Legend Biotech, Bellicum Pharmaceuticals and others.